MAC-545496

製品コードS6771 バッチS677101

化学情報

	Synonyms	N/A	Storage (From the date of receipt)	3 years -20°C powder
	化学式	C₁₈H₁₈ClN₅O₃S
	分子量	419.89	CAS No.	838810-96-1
Solubility (25°C)*	体外	DMSO	84 mg/mL (200.05 mM)
		Water	˂1 mg/mL
		Ethanol	˂1 mg/mL
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	MAC-545496 is a nanomolar glycopeptide-resistance-associated protein R(GraR) inhibitor with strong binding affinity to the full-length GraR protein (Kd ≤ 0.1 nM). MAC-545496 can reverse β-lactam resistance in methicillin-resistant strains and synergize with CAMPs. MAC-545496 shows remarkable activity in macrophages and attenuates S. aureus virulence in a G. mellonella larvae infection model.
in vitro	MAC-545496 shows inhibition of mprF expression in a concentration-dependent manner; the half-maximal inhibitory concentration (IC50) is 0.0376 µg/mL—matching with the concentration range of the synergistic effect with cefuroxime. MAC-545496 only inhibits the citrate-induced biofilm formation in the wild type in a concentration-dependent manner, suggesting additional potential as a lead for drug discovery. Treatment of S. aureus-infected macrophages with different doses of MAC-545496 added 30 min after phagocytosis shows that the MAC-545496 halts S. aureus replication within macrophages starting at 0.5 µg/mL.^[1].
in vivo	MAC-545496 activity is evidenced by increased survival of the drug-treated larvae as compared to infected untreated ones. This corresponds to concentration-dependent killing of S. aureus in the hemolymph of the larvae observed from the CFUs recovered from the hemolymph 200 min after infection. This matchs with the attenuated virulence of the graR::Tn mutant relative to the wild type in Galleria. Treatment with MAC-545496 recapitulates the phenotype of ΔgraR and ΔgraS mutants, effectively inhibiting intracellular S. aureus growth.^[1].

プロトコル(参考用のみ)

細胞アッセイ	細胞株	RAW macrophages
	濃度	20 µg/mL
	反応時間	12 h
	実験の流れ	Stationary-phase cells are washed and diluted in serum-free RPMI (SF-RPMI) and used for infection of RAW macrophages at a multiplicity of infection of ten. One set of replicates for S. aureus USA300 contains MAC-545496 (20 µg/mL) so that the drug is present throughout every step of the experiment. Macrophages exposed to bacteria are centrifuged at 277g to synchronize infection and after 30 min at 37 °C in 5% CO₂, the medium is replaced with SF-RPMI containing gentamicin (100 µg/mL) for 1 h. Here, after phagocytosis, another set of S. aureus USA300 replicates are exposed to MAC-545496 along with gentamicin so that the drug is added after the bacteria are phagocytosed. For wells already treated with MAC-545496, the drug is added too. After gentamicin treatment, one set of wells are lysed by treatment with 0.5 ml of 0.1% Triton X-100 after washing with PBS. The remaining well for each infection is incubated with RPMI containing 5% (vol/vol) non-heat-inactivated FBS until 12 h after infection when the cells are lysed.
動物実験	動物モデル	Galleria mellonella larvae
	投薬量	10 µL/100 mg
	投与方法	IV

参考

[1] El-Halfawy OM, et al. Nat Chem Biol. 2020;16(2):143-149.

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。